A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Inclusion Criteria: 1. Male or female, age ≥ 18 years at screening. 2. Histologically or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma \[NSCLC\], breast, ovarian, bladder, pancreatic, gastrointestinal, or colon/colorectal cancer). 3. Receiving platinum- and/or gemcitabine-containing chemotherapy regimens on 14- or 21-day treatment cycles. 4. Platelet count \< 85 x 109/L at enrollment. 5. For Part B, experiencing a chemotherapy delay of ≥ 7 days due to CIT. 6. At least 2 scheduled chemotherapy cycles of the same treatment regimen as was used prior to enrollment. 7. E…